Bengaluru, India, 15 July, 2026: Immuneel Therapeutics Pvt. Ltd., an Indian company pioneering cell and gene therapy, has entered into a strategic Memorandum of Understanding (MoU) with Tata Memorial Centre (TMC), an aided institute under the Department of Atomic Energy and India’s leading comprehensive cancer treatment and research institutions, to accelerate clinical and translational research in advanced cell and gene therapies.
The collaboration marks a significant step toward strengthening India’s innovation ecosystem in oncology and improving access to next-generation therapies for patients with difficult-to-treat cancers. Through this partnership, Immuneel and TMC aim to combine their respective expertise in clinical research, product development, manufacturing, and cancer care to drive meaningful advancements in immunotherapy and precision medicine. The partnership also exemplifies the growing synergy between government-supported research institutions and Indian industry, reinforcing a collaborative approach to advancing innovation and building a technologically self-reliant and stronger nation.
Under the MoU, the two organisations will work together on a broad range of collaborative initiatives in cell and gene therapy, including clinical studies, translational research, manufacturing expansion, policy engagement, and educational programs. The partnership is designed to create a strategic framework for future projects focused on accelerating innovation and enhancing patient outcomes in India.
Dr. Navin Khattry, Deputy Director, Clinical Services – ACTREC said, “India stands at an important inflection point in the evolution of advanced therapeutics, and collaborations such as this are critical to building a globally competitive innovation ecosystem. Our partnership with Immuneel reflects a shared commitment to accelerating cutting-edge cell and gene therapy research while ensuring that transformative cancer treatments become more accessible to patients in India. By combining scientific innovation, clinical excellence, and indigenous capabilities, we hope to create meaningful impact in the future of oncology care.”
Amit Mookim, Board Director & CEO, Immuneel Therapeutics added, “This collaboration with Tata Memorial Centre is an important milestone in Immuneel’s mission to advance patient-centric cell and gene therapies from India for the world. The partnership enables us to work closely with one of the country’s foremost oncology institutions to accelerate clinical research, strengthen translational science, and expand the development of innovative therapies for patients with complex and relapsed cancers. Together, we aim to build a strong foundation for next-generation cancer care and contribute to the long-term growth of India’s advanced therapeutics landscape.”
Among the key projects currently identified under the collaboration is a Phase 2 extension study evaluating the safety and efficacy of IMN-003A cell therapy in patients with relapsed and refractory CD19 positive B-cell malignancies, including both adult and pediatric patients. The partnership will also explore a Phase 1/Phase 2 clinical study for IMN-006 cell therapy in patients with relapsed or refractory multiple myeloma.
In addition to clinical trials, the collaboration will focus on research activities involving basic and preclinical studies on pipeline products, co-development of novel therapeutic entities, and initiatives aimed at expanding manufacturing capabilities for advanced therapies in India. The MoU also outlines plans for educational programs and knowledge-sharing initiatives to build awareness and strengthen expertise in the rapidly evolving field of cell and gene therapy.
Another important area of collaboration will include policy engagement efforts to help shape frameworks for first-in-human clinical trials and support the broader development of India’s regenerative medicine and advanced therapeutics ecosystem.
By combining TMC’s extensive clinical and research expertise in oncology with Immuneel’s capabilities in cell therapy development and manufacturing, the partnership aims to create a robust platform for innovation that can potentially make advanced cancer treatments more accessible and affordable for Indian patients.
The collaboration is expected to support the generation of critical clinical and laboratory data, foster scientific innovation, and contribute to building indigenous capabilities in advanced therapeutics. It also reflects a growing commitment within India’s healthcare and biotechnology sectors to develop globally competitive, patient-centric solutions for cancer care.
